{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:02:09Z","timestamp":1791849729328,"version":"4.3.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,23]]},"DOI":"10.7759\/cureus.42332","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T17:48:55Z","timestamp":1690134535000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparing Intravenous Labetalol and Intravenous Hydralazine for Managing Severe Gestational Hypertension"],"prefix":"10.7759","author":[{"given":"Eustace","family":"Ehikioya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maame Akosua E","family":"Beeko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafia","family":"Abanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namtor Nicole I","family":"Abah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience N","family":"Nwimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa Kwame A","family":"Beeko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyinyechukwu B","family":"Nwachukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C","family":"Okoroafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/105918","article-title":"A comprehensive review of hypertension in pregnancy","volume":"2012","author":"Mustafa R","year":"2012","unstructured":"Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012, 2012:105918. 10.1155\/2012\/105918","journal-title":"J Pregnancy"},{"key":"ref2","article-title":"Hypertension in pregnancy","author":"Miller DA","year":"2013","unstructured":"Miller DA. Hypertension in pregnancy. Current Diagnosis and Treatment, Obstetrics and Gynecology. Decherney AH, Nathan l, Goodwin TM, Laufer (ed): McGraw Hill, USA; 2013. 11th Edition:454-64."},{"key":"ref3","unstructured":"NHS Maternity statistics - England, 2009-2010. (2010). Accessed. 4\/23\/2023: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/nhs-maternity-statistics\/2009-10."},{"key":"ref4","article-title":"Hypertensive disorders","author":"Cunninghan FG","year":"2018","unstructured":"Cunninghan FG, Hauth JC, Leveno KJ, Gilstrap L, Bloom SL, Wenstrom KD. Hypertensive disorders. Williams Obstetrics. McGraw Hill, USA; 2018. 25e."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4236\/ojog.2014.49080","article-title":"Serum magnesium levels in healthy pregnant and pre-eclamptic patients","volume":"9","author":"Adekanle DA","year":"2014","unstructured":"Adekanle DA, Adeyemo OT, Adeniyi AA, et al.. Serum magnesium levels in healthy pregnant and pre-eclamptic patients\r\n. Scientific Research . 2014, 9:10.4236\/ojog.2014.49080","journal-title":"Scientific Research"},{"key":"ref6","article-title":"Centre for Maternal and Child Enquiries (CMACE) Perinatal Mortality 2008","author":"Centre for Maternal and Child Enquiries","year":"2010","unstructured":"Centre for Maternal and Child Enquiries . Centre for Maternal and Child Enquiries (CMACE) Perinatal Mortality 2008. CMACE, United Kingdom; 2010."},{"key":"ref7","article-title":"Maternal mortality: current situation","volume":"2","author":"Uzoigwe SA","year":"2013","unstructured":"Uzoigwe SA. Maternal mortality: current situation. Gazette of Medicine. 2013, 2:137-9.","journal-title":"Gazette of Medicine"},{"key":"ref8","article-title":"Dewhurt's Textbook of Obstetrics & Gynaecology","author":"Edmonds DK","year":"2007","unstructured":"Edmonds DK. Dewhurt's Textbook of Obstetrics & Gynaecology. Edmonds DK (ed): Black Well Publishing, United Kingdom; 2007."},{"key":"ref9","article-title":"Pregnancy and the risk of autoimmune disease: an exploration","volume":"2","author":"O'Donoghue K","year":"2011","unstructured":"O'Donoghue K. Pregnancy and the risk of autoimmune disease: an exploration. Chimerism. 2011, 2:84-5.","journal-title":"Chimerism"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00036.x","article-title":"Use of antihypertensive drugs during pregnancy and lactation","volume":"26","author":"Ghanem FA","year":"2008","unstructured":"Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther. 2008, 26:38-49. 10.1111\/j.1527-3466.2007.00036.x","journal-title":"Cardiovasc Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04002.x","article-title":"How to manage hypertension in pregnancy effectively","volume":"72","author":"Magee LA","year":"2011","unstructured":"Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011, 72:394-401. 10.1111\/j.1365-2125.2011.04002.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.106.075895","article-title":"Update on the use of antihypertensive drugs in pregnancy","volume":"51","author":"Podymow T","year":"2008","unstructured":"Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008, 51:960-9. 10.1161\/HYPERTENSIONAHA.106.075895","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002252.pub2","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","author":"Abalos E","year":"2007","unstructured":"Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007, CD002252. 10.1002\/14651858.CD002252.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2014.01.003","article-title":"Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy","volume":"4","author":"Magee LA","year":"2014","unstructured":"Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014, 4:105-45. 10.1016\/j.preghy.2014.01.003","journal-title":"Pregnancy Hypertens"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.54112\/bcsrj.v2022i1.147","article-title":"The prevalence of effectiveness of bolus dose of I\/V hydralazine versus I\/V labetalol for the earlier control of blood pressure in severe preeclamptic patient: a comparative study","volume":"1","author":"Kumari S","year":"2022","unstructured":"Kumari S, Dars S, Zahra S, et al.. The prevalence of effectiveness of bolus dose of I\/V hydralazine versus I\/V labetalol for the earlier control of blood pressure in severe preeclamptic patient: a comparative study. Biological and Clinical Sciences Research Journal. 2022, 1:5-10. 10.54112\/bcsrj.v2022i1.147","journal-title":"Biological and Clinical Sciences Research Journal"},{"key":"ref16","article-title":"Short term treatment of severe hypertension of pregnancy: a comparison of nicardipine and labetalol","volume":"28","author":"Elastrous S","year":"2012","unstructured":"Elastrous S, Nonira S, OuanesBesbes l, Marghi S, Boussarssar M, Sakkhouhi M. Short term treatment of severe hypertension of pregnancy: a comparison of nicardipine and labetalol.  Intensive Care Medicine. 2012, 28:1281-6.","journal-title":"Intensive Care Medicine"},{"key":"ref17","article-title":"Annual Report for the Period: July 1, 2017 - June 30, 2018","author":"Pressman EK","year":"2018","unstructured":"Pressman EK. Annual Report for the Period: July 1, 2017 - June 30, 2018 . Pressman EK (ed): Uni. of Rochester, USA; 2018."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001449.pub3","article-title":"Drugs for treatment of very high blood pressure during pregnancy","volume":"2013","author":"Duley L","year":"2013","unstructured":"Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013, 2013:CD001449. 10.1002\/14651858.CD001449.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2019.09.019","article-title":"First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis","volume":"18","author":"Alavifard S","year":"2019","unstructured":"Alavifard S, Chase R, Janoudi G, Chaumont A, Lanes A, Walker M, Gaudet L. First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis. Pregnancy Hypertens. 2019, 18:179-87. 10.1016\/j.preghy.2019.09.019","journal-title":"Pregnancy Hypertens"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)91297-p","article-title":"A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy","volume":"162","author":"Sibai BM","year":"2014","unstructured":"Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 2014, 162:960-7. 10.1016\/0002-9378(90)91297-p","journal-title":"Am J Obstet Gynecol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09972","article-title":"Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial","volume":"70","author":"Webster LM","year":"2017","unstructured":"Webster LM, Myers JE, Nelson-Piercy C, et al.. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension. 2017, 70:915-22. 10.1161\/HYPERTENSIONAHA.117.09972","journal-title":"Hypertension"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6382.1927","article-title":"Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy","volume":"286","author":"Fidler J","year":"1983","unstructured":"Fidler J, Smith V, Fayers P, De Swiet M. Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed). 1983, 286:1927-30. 10.1136\/bmj.286.6382.1927","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref23","article-title":"Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa","volume":"291","author":"Gallery ED","year":"2011","unstructured":"Gallery ED, Ross MR, Gyory AZ. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. BMJ . 2011, 291:563-6.","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13649","article-title":"Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"84","author":"Sridharan K","year":"2018","unstructured":"Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018, 84:1906-16. 10.1111\/bcp.13649","journal-title":"Br J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1977.tb12616.x","article-title":"Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects","volume":"84","author":"Redman CW","year":"1977","unstructured":"Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol. 1977, 84:419-26. 10.1111\/j.1471-0528.1977.tb12616.x","journal-title":"Br J Obstet Gynaecol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7421489","article-title":"Pharmacological effect of quercetin in hypertension and its potential application in pregnancy-induced hypertension: review of in vitro, in vivo, and clinical studies","volume":"2018","author":"O\u017carowski M","year":"2018","unstructured":"O\u017carowski M, Miko\u0142ajczak P\u0141, Kujawski R, Wielgus K, Klejewski A, Wolski H, Seremak-Mrozikiewicz A. Pharmacological effect of quercetin in hypertension and its potential application in pregnancy-induced hypertension: review of in vitro, in vivo, and clinical studies. Evid Based Complement Alternat Med. 2018, 2018:7421489. 10.1155\/2018\/7421489","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1503","article-title":"Drug-induced liver injury in GI practice","volume":"4","author":"Sandhu N","year":"2020","unstructured":"Sandhu N, Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020, 4:631-45. 10.1002\/hep4.1503","journal-title":"Hepatol Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001456","article-title":"In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review","volume":"35","author":"Fitton CA","year":"2017","unstructured":"Fitton CA, Steiner MF, Aucott L, Pell JP, Mackay DF, Fleming M, McLay JS. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017, 35:2123-37. 10.1097\/HJH.0000000000001456","journal-title":"J Hypertens"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0545-1","article-title":"Hypertension in pregnancy: natural history and treatment options","volume":"17","author":"Foo L","year":"2015","unstructured":"Foo L, Tay J, Lees CC, McEniery CM, Wilkinson IB. Hypertension in pregnancy: natural history and treatment options. Curr Hypertens Rep. 2015, 17:36. 10.1007\/s11906-015-0545-1","journal-title":"Curr Hypertens Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002863","article-title":"Oral beta\u2010blockers for mild to moderate hypertension during pregnancy","volume":"2003","author":"Magee L","year":"2003","unstructured":"Magee L, Duley L. Oral beta\u2010blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003, 2003:CD002863. 10.1002\/14651858.CD002863","journal-title":"Cochrane Database Syst Rev"},{"key":"ref31","article-title":"The effect of beta-blockers on fetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study","volume":"31(3)","author":"Baard J","year":"2020","unstructured":"Baard J, Azibani F, Osman A, Dowling W, Rayner B, Sliwa K . The effect of beta-blockers on fetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr. 2020, 31(3):136-41.","journal-title":"Cardiovasc J Afr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20191230","article-title":"Hydralazine versus labetalol for acute control of blood pressure in patients with severe pre-eclampsia: a randomized controlled trial","volume":"8","author":"Gaur N","year":"2019","unstructured":"Gaur N, Kathuria P. Hydralazine versus labetalol for acute control of blood pressure in patients with severe pre-eclampsia: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol. 2019, 8:1626-9. 10.18203\/2320-1770.ijrcog20191230","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(99)00113-X","article-title":"Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials","volume":"88","author":"Magee LA","year":"2008","unstructured":"Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol. 2008, 88:15-26. 10.1016\/S0301-2115(99)00113-X","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1081\/PRG-120028291","article-title":"Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review","volume":"23","author":"Waterman EJ","year":"2004","unstructured":"Waterman EJ, Magee LA, Lim KI, Skoll A, Rurak D, von Dadelszen P. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy. 2004, 23:155-69. 10.1081\/PRG-120028291","journal-title":"Hypertens Pregnancy"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2020.01.011","article-title":"The flipside of hydralazine in pregnancy: a systematic review and meta-analysis","volume":"19","author":"Antza C","year":"2020","unstructured":"Antza C, Dimou C, Doundoulakis I, et al.. The flipside of hydralazine in pregnancy: a systematic review and meta-analysis. Pregnancy Hypertens. 2020, 19:177-86. 10.1016\/j.preghy.2020.01.011","journal-title":"Pregnancy Hypertens"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002252.pub4","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos E","year":"2018","unstructured":"Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018, 10:CD002252. 10.1002\/14651858.CD002252.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref37","article-title":"Antihypertensive agents","author":"Benowitz NL","year":"2021","unstructured":"Benowitz NL. Antihypertensive agents. Basic & Clinical Pharmacology. Katzung BG, Vanderah TW (ed): McGraw Hill, USA; 2021. 15e."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001185","article-title":"\u03b2-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study","volume":"2","author":"Meidahl Petersen K","year":"2012","unstructured":"Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al.. \u03b2-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012, 2:e001185. 10.1136\/bmjopen-2012-001185","journal-title":"BMJ Open"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2007.00738.x","article-title":"A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial","volume":"47","author":"Hennessy A","year":"2007","unstructured":"Hennessy A, Thornton CE, Makris A, Ogle RF, Henderson-Smart DJ, Gillin AG, Child A. A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial. Aust N Z J Obstet Gynaecol. 2007, 47:279-85. 10.1111\/j.1479-828X.2007.00738.x","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.36347\/sjams.2016.v04i11.028","article-title":"A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension (PIH)","volume":"4","author":"Nabanita D","year":"2016","unstructured":"Nabanita D, Chandra G, Swagata B, et al.. A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension (PIH). Sch J App Med Sci\r\n. 2016, 4:3996-9. 10.36347\/sjams.2016.v04i11.028","journal-title":"Sch J App Med Sci"},{"key":"ref41","article-title":"ESC Guidelines on the management of cardiovascular diseases during pregnancy","volume":"32","author":"Regitz-Zagrosek V","year":"2011","unstructured":"Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011, 32:3147-97.","journal-title":"Eur Heart J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4103\/npmj.npmj_275_20","article-title":"Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial","volume":"27","author":"Adebayo JA","year":"2020","unstructured":"Adebayo JA, Nwafor JI, Lawani LO, Esike CO, Olaleye AA, Adiele NA. Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial. Niger Postgrad Med J. 2020, 27:317-24. 10.4103\/npmj.npmj_275_20","journal-title":"Niger Postgrad Med J"},{"key":"ref43","article-title":"Emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia","volume":"514","author":"Committee on Obstetric Practice","year":"2011","unstructured":"Committee on Obstetric Practice. Emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Obstet Gynecol. 2011, 514:1-4.","journal-title":"Obstet Gynecol"},{"key":"ref44","unstructured":"ACOG Guidance. emergency treatment for severe hypertension in pregnancy. (2017). Accessed: 3\/1\/2023: https:\/\/www.obgproject.com\/2017\/04\/16\/acog-guidance-emergency-treatment-severe-hypertension\/."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2006.02.015","article-title":"Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial","volume":"128","author":"Vigil-De Gracia P","year":"2006","unstructured":"Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, L\u00f3pez JC. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006, 128:157-62. 10.1016\/j.ejogrb.2006.02.015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1097\/AOG.0b013e3182a9ea68","article-title":"Oral nifedipine or intravenous labetalol for hypertensive emergency. A randomized controlled trial","volume":"122","author":"Shekhar S","year":"2013","unstructured":"Shekhar S, Sharma C,  Chanderdeep,Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency. A randomized controlled trial. Obstet Gynecol. 2013, 122:1057-63.","journal-title":"Obstet Gynecol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2011.03151.x","article-title":"Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial","volume":"119","author":"Raheem IA","year":"2012","unstructured":"Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012, 119:78-85. 10.1111\/j.1471-0528.2011.03151.x","journal-title":"BJOG"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.10.111","article-title":"Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy","volume":"178","author":"Shi Q","year":"2015","unstructured":"Shi Q, Leng W, Yao Q, Mi C, Xing A. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy. Int J Cardiol. 2015, 178:162-4. 10.1016\/j.ijcard.2014.10.111","journal-title":"Int J Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/10641955.2022.2056196","article-title":"Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials","volume":"41","author":"Wu HZ","year":"2022","unstructured":"Wu HZ, Cheng Y, Yu D, Li JB, Jiang YF, Zhu ZN. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. Hypertens Pregnancy. 2022, 41:126-38. 10.1080\/10641955.2022.2056196","journal-title":"Hypertens Pregnancy"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.704023","article-title":"Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics","volume":"118","author":"Johnson JA","year":"2008","unstructured":"Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008, 118:1383-93. 10.1161\/CIRCULATIONAHA.107.704023","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.332.12243","article-title":"Comparison of hydralazine and labetalol to lower severe hypertension in pregnancy","volume":"33","author":"Khan A","year":"2017","unstructured":"Khan A, Hafeez S, Nasrullah FD. Comparison of hydralazine and labetalol to lower severe hypertension in pregnancy. Pak J Med Sci. 2017, 33:466-70. 10.12669\/pjms.332.12243","journal-title":"Pak J Med Sci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.15406\/ogij.2017.06.00222","article-title":"Intravenous hydrallazine or intravenous labetalol in severe hypertension in pregnancy: a randomized clinical trial","volume":"6","author":"Mmom CF","year":"2017","unstructured":"Mmom CF, Ogu RN, Orazulike NC, Uzoigwe SA. Intravenous hydrallazine or intravenous labetalol in severe hypertension in pregnancy: a randomized clinical trial. Obstet GynecolInt J. 2017, 6:00222. 10.15406\/ogij.2017.06.00222","journal-title":"Obstet GynecolInt J"},{"key":"ref53","article-title":"A comparison of Hydrallazine and Labetalol in the management of severe pre eclampsia","volume":"3","author":"Nombur LI","year":"2014","unstructured":"Nombur LI, Agida ET, Isah AY, Ekele BA. A comparison of Hydrallazine and Labetalol in the management of severe pre eclampsia. J Womens Health Care. 2014, 3:6.","journal-title":"J Womens Health Care"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2013.08.001","article-title":"Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial","volume":"4","author":"Delgado De Pasquale S","year":"2014","unstructured":"Delgado De Pasquale S, Velarde R, Reyes O, De La Ossa K. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial. Pregnancy Hypertens. 2014, 4:19-22. 10.1016\/j.preghy.2013.08.001","journal-title":"Pregnancy Hypertens"},{"key":"ref55","article-title":"A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension","volume":"4","author":"Deka N","year":"2016","unstructured":"Deka N, DasGokul C, Baishya S, Yadav S. A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension. Sch J App Med Sci. 2016, 4:3996-9.","journal-title":"Sch J App Med Sci"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.12669%2Fpjms.332.12243","article-title":"Comparison of Hydralazine and labetalol to lower severe hypertension in pregnancy","volume":"33","author":"Ayesha khan","year":"2017","unstructured":"Ayesha khan, Sajida Hafeez, Farah, DN. Comparison of Hydralazine and labetalol to lower severe hypertension in pregnancy. Park J Med Sci. 2017, 33:466-70. 10.12669%2Fpjms.332.12243","journal-title":"Park J Med Sci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2022.05.001","article-title":"Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: a randomized controlled trial","volume":"29","author":"Muhammad S","year":"2022","unstructured":"Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: a randomized controlled trial. Pregnancy Hypertens. 2022, 29:1-6. 10.1016\/j.preghy.2022.05.001","journal-title":"Pregnancy Hypertens"},{"key":"ref58","article-title":"Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy","volume":"71","author":"Ashe RG","year":"1987","unstructured":"Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J. 1987, 71:354-6.","journal-title":"S Afr Med J"},{"key":"ref59","article-title":"Comparison of oral nifedipine with intravenous hydralazine for acute hypertensive emergencies of pregnancy","volume":"30","author":"Sabir R","year":"2016","unstructured":"Sabir R, Yasmin S, Abbas G. Comparison of oral nifedipine with intravenous hydralazine for acute hypertensive emergencies of pregnancy. J Postgrad Med Inst. 2016, 30:328-30.","journal-title":"J Postgrad Med Inst"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s13224-017-1053-9","article-title":"Comparison of efficacy and safety of intravenous Labetalol versus Hydralazine for management of severe hypertension in pregnancy","volume":"68","author":"Patel P","year":"2018","unstructured":"Patel P, Koli D, Maitra N, Sheth T, Vaishnav P. Comparison of efficacy and safety of intravenous Labetalol versus Hydralazine for management of severe hypertension in pregnancy. J Obstet Gynaecol India. 2018, 68:376-81. 10.1007\/s13224-017-1053-9","journal-title":"J Obstet Gynaecol India"},{"key":"ref61","article-title":"Comparison of Maternal Hypotension after administration of labetalol versus hydralazine in treating patients having severe pregnancy induced hypertension","volume":"11","author":"Shabnum T","year":"2017","unstructured":"Shabnum T, Amna S, Tanzila Y. Comparison of Maternal Hypotension after administration of labetalol versus hydralazine in treating patients having severe pregnancy induced hypertension. JMHS. 2017, 11:541.","journal-title":"JMHS"},{"key":"ref62","article-title":"A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy","volume":"70","author":"Mabie WC","year":"1987","unstructured":"Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987, 70:328-33.","journal-title":"Obstet Gynecol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3109\/10641958209139860","article-title":"Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy","volume":"1","author":"Garden A","year":"1982","unstructured":"Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin Exp Hypertens B. 1982, 1:371-83. 10.3109\/10641958209139860","journal-title":"Clin Exp Hypertens B"},{"key":"ref64","article-title":"A comparative study of IV labetalol and IV hydralazine on mean arterial blood pressure","volume":"2016","author":"Trivedi S","year":"2016","unstructured":"Trivedi S, Vyas L, Ratnu L, Gupta P, Agarwal P, Patel T. A comparative study of IV labetalol and IV hydralazine on mean arterial blood pressure. Sch J App Med Sci. 2016, 2016:2256-9.","journal-title":"Sch J App Med Sci"},{"key":"ref65","article-title":"A comparative study of antihypertensive efficacy and perinatal safety of intravenous hydralazine and labetalol in pregnancy induced hypertensive crisis","volume":"2","author":"Pooja S","year":"2018","unstructured":"Pooja S, Kdura M, Rawat RP, et al.. A comparative study of antihypertensive efficacy and perinatal safety of intravenous hydralazine and labetalol in pregnancy induced hypertensive crisis. Int J Clin Obstet Gynaecol. 2018, 2:11-3.","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"ref66","article-title":"Pregnancy-induced hypertension and preeclampsia: a review of current antihypertensive pharmacologic treatment options","volume":"1","author":"Anderson NR","year":"2013","unstructured":"Anderson NR, Undeberg M, Bastianelli KMS. Pregnancy-induced hypertension and preeclampsia: a review of current antihypertensive pharmacologic treatment options. Austin J PharmacolTher. 2013, 1:8-13.","journal-title":"Austin J PharmacolTher"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmacro.2008.04.003","article-title":"Health and infrastructure in a model of endogenous growth","volume":"30","author":"Agenor PR","year":"2008","unstructured":"Agenor PR. Health and infrastructure in a model of endogenous growth. J Macroeconom. 2008, 30:1407-22. 10.1016\/j.jmacro.2008.04.003","journal-title":"J Macroeconom"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v12i2.11","article-title":"Ecalmpsia: maternal and fetal outcome","volume":"12","author":"Jido TA","year":"2012","unstructured":"Jido TA. Ecalmpsia: maternal and fetal outcome. Afr Health Sci. 2012, 12:148-52. 10.4314\/ahs.v12i2.11","journal-title":"Afr Health Sci"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1080\/01443610400009451","article-title":"Maternal and fetal outcome in eclamptic patients in Benin City, Nigeria","volume":"24","author":"Onuh SO","year":"2004","unstructured":"Onuh SO, Aisien AO. Maternal and fetal outcome in eclamptic patients in Benin City, Nigeria. J Obstet Gynaecol. 2004, 24:765-8. 10.1080\/01443610400009451","journal-title":"J Obstet Gynaecol"},{"key":"ref70","article-title":"Maternal outcome in Eclamptic patients in Abuja, Nigeria- 5 year review","volume":"10","author":"Efetie RE","year":"2007","unstructured":"Efetie RE, Okafor UV. Maternal outcome in Eclamptic patients in Abuja, Nigeria- 5 year review. Niger J. 2007, 10:","journal-title":"Niger J"},{"key":"ref71","article-title":"Research Methodology with Statistics for Health and Social Sciences.","author":"Araoye MO","year":"2003","unstructured":"Araoye MO. Research Methodology with Statistics for Health and Social Sciences.\r\n. Nathadex Publishers , Nigeria; 2003."},{"key":"ref72","article-title":"Management of severe preeclampsia, eclampsia, and severe hypertensive crises in Benin City, Nigeria, using a combination of magnesium sulphate and labetalol","volume":"23","author":"Unuigbe JA","year":"2011","unstructured":"Unuigbe JA, Ebomwonyi IO, Sule Z, et al.. Management of severe preeclampsia, eclampsia, and severe hypertensive crises in Benin City, Nigeria, using a combination of magnesium sulphate and labetalol\r\n. J Obstet Gynecol . 2011, 23:54-7.","journal-title":"J Obstet Gynecol"},{"key":"ref73","article-title":"Maternal and perinatal outcome in severe preeclampsia and eclampsia","volume":"5","author":"Saxena N","year":"2016","unstructured":"Saxena N, Amarjeet K, Yogeshwar N. Maternal and perinatal outcome in severe preeclampsia and eclampsia. Int J Reprod Contracept Obst Gynec. 2016, 5:2171-7.","journal-title":"Int J Reprod Contracept Obst Gynec"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164342-comparing-intravenous-labetalol-and-intravenous-hydralazine-for-managing-severe-gestational-hypertension","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:24Z","timestamp":1707508884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164342-comparing-intravenous-labetalol-and-intravenous-hydralazine-for-managing-severe-gestational-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,23]]},"references-count":73,"URL":"https:\/\/doi.org\/10.7759\/cureus.42332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,23]]}}}